Boothbay Fund Management LLC purchased a new position in shares of STERIS plc (NYSE:STE - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 2,443 shares of the medical equipment provider's stock, valued at approximately $502,000.
Several other large investors have also bought and sold shares of STE. Avalon Trust Co acquired a new position in shares of STERIS during the fourth quarter worth about $30,000. Human Investing LLC bought a new stake in shares of STERIS in the fourth quarter worth $31,000. Anfield Capital Management LLC boosted its holdings in STERIS by 100.0% during the fourth quarter. Anfield Capital Management LLC now owns 182 shares of the medical equipment provider's stock worth $37,000 after purchasing an additional 91 shares during the last quarter. Central Pacific Bank Trust Division increased its stake in STERIS by 65.5% in the 4th quarter. Central Pacific Bank Trust Division now owns 192 shares of the medical equipment provider's stock valued at $39,000 after buying an additional 76 shares during the last quarter. Finally, Manchester Capital Management LLC lifted its position in STERIS by 182.7% during the 4th quarter. Manchester Capital Management LLC now owns 212 shares of the medical equipment provider's stock worth $44,000 after buying an additional 137 shares in the last quarter. 94.69% of the stock is currently owned by institutional investors and hedge funds.
STERIS Trading Down 0.1 %
Shares of STE stock traded down $0.13 on Tuesday, hitting $224.18. The company had a trading volume of 113,743 shares, compared to its average volume of 537,969. STERIS plc has a twelve month low of $200.98 and a twelve month high of $248.24. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.40 and a current ratio of 2.13. The firm has a market cap of $22.03 billion, a P/E ratio of 47.56 and a beta of 0.96. The stock's 50-day moving average is $223.14 and its two-hundred day moving average is $218.76.
STERIS (NYSE:STE - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $2.32 earnings per share for the quarter, missing analysts' consensus estimates of $2.33 by ($0.01). STERIS had a return on equity of 13.91% and a net margin of 8.66%. On average, equities research analysts anticipate that STERIS plc will post 9.08 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
STE has been the topic of several recent analyst reports. Stephens reaffirmed an "overweight" rating and set a $240.00 price target on shares of STERIS in a research report on Thursday, February 6th. Needham & Company LLC reiterated a "hold" rating on shares of STERIS in a research note on Monday, April 7th. JMP Securities restated a "market outperform" rating and set a $265.00 price objective on shares of STERIS in a research note on Thursday, April 10th. Finally, Piper Sandler lifted their price target on STERIS from $260.00 to $265.00 and gave the stock an "overweight" rating in a report on Monday, February 3rd. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $258.75.
View Our Latest Report on STE
About STERIS
(
Free Report)
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
Further Reading

Before you consider STERIS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STERIS wasn't on the list.
While STERIS currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.